Cargando…

Activation and function of receptor tyrosine kinases in human clear cell renal cell carcinomas

BACKGROUND: The receptor tyrosine kinases (RTKs) play critical roles in the development of cancers. Clear cell renal cell carcinoma (ccRCC) accounts for 75% of the RCC. The previous studies on the RTKs in ccRCCs mainly focused on their gene expressions. The activation and function of the RTKs in ccR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Qing, Liu, Jian-He, Liu, Jing-Li, Qi, Chun-Ting, Yan, Lei, Chen, Yu, Yu, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6833303/ https://www.ncbi.nlm.nih.gov/pubmed/31690270 http://dx.doi.org/10.1186/s12885-019-6159-2

Ejemplares similares

Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor
por: Zhang, Hailiang, et al.
Publicado: (2023)

Gas6 and the Receptor Tyrosine Kinase Axl in Clear Cell Renal Cell Carcinoma
por: Gustafsson, Anna, et al.
Publicado: (2009)

Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma
por: Sekino, Yohei, et al.
Publicado: (2022)

High expression of FER tyrosine kinase predicts poor prognosis in clear cell renal cell carcinoma
por: WEI, CAN, et al.
Publicado: (2013)

Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in  Clear - Cell Renal Cell Carcinoma (ccRCC)
por: Bielecka, Zofia F., et al.
Publicado: (2013)

Connexin43 is associated with the progression of clear cell renal carcinoma and is regulated by tangeretin to sygergize with tyrosine kinase inhibitors
por: Lai, Yongchang, et al.
Publicado: (2023)

Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma
por: Yu, H, et al.
Publicado: (2015)

c-Met and EPHA7 Receptor Tyrosine Kinases Are Related to Prognosis in Clear Cell Renal Cell Carcinoma: Focusing on the Association with Myoferlin Expression
por: Jung, Minsun, et al.
Publicado: (2022)

Identification of a 6-Gene Signature Associated with Resistance to Tyrosine Kinase Inhibitors: Prognosis for Clear Cell Renal Cell Carcinoma
por: Li, Qinke, et al.
Publicado: (2020)

MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients
por: Lukamowicz-Rajska, Magdalena, et al.
Publicado: (2016)

Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor
por: Xia, Yu, et al.
Publicado: (2017)

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma
por: Wada, Yoshihiro, et al.
Publicado: (2012)

Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
por: Rassy, Elie, et al.
Publicado: (2020)

Role of Receptor Tyrosine Kinase Signaling in Renal Fibrosis
por: Liu, Feng, et al.
Publicado: (2016)

Comparison of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma with rhabdoid and sarcomatoid differentiations
por: Wang, Kun, et al.
Publicado: (2023)

Decreased expression of TXNIP predicts poor prognosis in patients with clear cell renal cell carcinoma
por: Gao, Yuan, et al.
Publicado: (2020)

Common reduction of the Raf kinase inhibitory protein in clear cell renal cell carcinoma
por: Hill, Brianne, et al.
Publicado: (2014)

Identification of anaplastic lymphoma kinase fusions in clear cell renal cell carcinoma
por: Chen, Wei, et al.
Publicado: (2020)

Expression of CIDE proteins in clear cell renal cell carcinoma and their prognostic significance
por: Yu, Ming, et al.
Publicado: (2013)

Role of Metabolic Reprogramming of Long non-coding RNA in Clear Cell Renal Cell Carcinoma
por: Zhang, Huijie, et al.
Publicado: (2022)

The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma
por: Zhuang, Jintao, et al.
Publicado: (2014)

Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor–Resistant Clear Cell Renal Cell Carcinoma()
por: Jang, Jiryeon, et al.
Publicado: (2017)

KDF1, a Novel Tumor Suppressor in Clear Cell Renal Cell Carcinoma
por: Zheng, Jing-min, et al.
Publicado: (2021)

Prognostic significance of pseudocapsule status in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
por: Xi, Wei, et al.
Publicado: (2021)

Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
por: Lai, Yongchang, et al.
Publicado: (2018)

Expression and clinical significance of DOK3 in renal clear cell carcinoma
por: Wang, Yi-Fan, et al.
Publicado: (2023)

miRNAs in Prediction of Prognosis in Clear Cell Renal Cell Carcinoma
por: Ran, LongJiao, et al.
Publicado: (2017)

Emerging Targets in Clear Cell Renal Cell Carcinoma
por: Chen, Yu-Wei, et al.
Publicado: (2022)

Expression and epigenetic regulatory mechanism of BNIP3 in clear cell renal cell carcinoma
por: Shao, Yanxiang, et al.
Publicado: (2018)

Genomic Analysis Reveals Novel Specific Metastatic Mutations in Chinese Clear Cell Renal Cell Carcinoma
por: Meng, Hui, et al.
Publicado: (2020)

Paraneoplastic Eosinophilia in Clear Cell Renal Cell Carcinoma
por: Zhou, Wei-Wei, et al.
Publicado: (2015)

Prognostic and Predictive Values of Subcellular Localisation of RET in Renal Clear-Cell Carcinoma
por: Wang, Lei, et al.
Publicado: (2016)

Third Generation Tyrosine Kinase Inhibitors and Their Development in Advanced Renal Cell Carcinoma
por: Bukowski, Ronald M.
Publicado: (2012)

Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
por: Vasudev, Naveen S., et al.
Publicado: (2011)

Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal Cell Carcinoma—Future or the Past?
por: Michaelis, Jakob, et al.
Publicado: (2022)

Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
por: Catalano, Martina, et al.
Publicado: (2022)

Immune-related risk prognostic model for clear cell renal cell carcinoma: Implications for immunotherapy
por: Chen, Ronghui, et al.
Publicado: (2023)

AB137. Decreased expression of receptor tyrosine kinase of EphB1 protein in renal cell carcinomas
por: Wang, Longxin, et al.
Publicado: (2016)

Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma
por: Franczyk, Beata, et al.
Publicado: (2023)

Podoplanin associates with adverse postoperative prognosis of patients with clear cell renal cell carcinoma
por: Xia, Yu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fdn8p59pu3i7s91j97tj0jihs8